Zynex, Inc. is a medical technology company specialized in the manufacturing and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The Companyâ€™s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâ€™s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave, M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Private Labeled Rehabilitation Products, which include Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces, Bracing (Knee and Wrist), and Dynacomp, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter.

Employees

1,000

Sector

Advanced Medical Equipment & Technology

More about the company

Market Closed - OTC Markets 19:56:45 26/03/2026 GMT			5-day change	1st Jan Change
0.0550 ^USD	+5.77%		-.--%	-56.35%

03-26	Altivera Medical Holdings, LLC acquired Zynex, Inc.	CI
03-26	Zynex, Inc. Secures Term Loan Credit Agreement Finalized	CI

Market Cap	3.83M 3.29M 3.1M 2.83M 5.27M 363M 5.3M 36.7M 14.2M 186M 14.38M 14.06M 590M	P/E 2023	40.3x	P/E 2024	89x
Enterprise Value	38.02M 32.69M 30.76M 28.07M 52.38M 3.6B 52.65M 364M 141M 1.84B 143M 140M 5.86B	EV / Sales 2023	2.17x	EV / Sales 2024	1.5x
Free-Float	38.37%	Yield 2023 *	-	Yield 2024	-

03-26	Altivera Medical Holdings, LLC acquired Zynex, Inc.	CI
03-26	Zynex, Inc. Secures Term Loan Credit Agreement Finalized	CI
03-26	Zynex, Inc. Emerged from Bankruptcy	CI
03-20	Court confirms Zynex plan of reorganization on March 19, 2026 - SEC filing	RE
03-19	Third Amended Reorganization Plan Approved for Zynex, Inc.	CI
02-19	Zynex Inc says SEC concluded investigation into Zynex, no enforcement action planned	RE
02-17	Zynex Inc resolves federal investigation into business practices	RE
02-10	Notice of Auction Cancellation and Designation of Successful Bidder Filed by Zynex, Inc.	CI
02-07	Third Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI
02-04	Zynex, Inc. Announces New In-Network Provider Status with Humana	CI
02-02	Second Amended Joint Disclosure Statement Conditionally Approved and Combined Hearing of Second Amended Disclosure Statement and Reorganization Plan Approved for Zynex, Inc.	CI
02-01	Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI
01-29	First Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI

01/08/25	RBC Capital Adjusts Price Target on Zynex to $2 From $3, Maintains Sector Perform Rating	MT
01/08/25	HC Wainwright Downgrades Zynex to Neutral From Buy	MT
31/07/25	Medtech Zynex's Q2 revenue falls more than expected, names new CEO, suspends forecast	RE
15/07/25	RBC Cuts Price Target on Zynex to $3 From $4, Keeps Sector Perform Rating	MT
30/04/25	RBC Cuts Price Target on Zynex to $4 From $5, Keeps Sector Perform Rating	MT

Zynex, Inc. Share Price

Stocks

ZYXI

US98986M1036

Advanced Medical Equipment & Technology

Valuation : Zynex, Inc.

Chart: Zynex, Inc.

Latest news : Zynex, Inc.

Last Transcript : Zynex, Inc.

Analysts' recommendations : Zynex, Inc.

Press Releases : Zynex, Inc.

News in other languages : Zynex, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Zynex, Inc.

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

03-27	ZYXIQ Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026	NE
03-26	ZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements	PR
03-26	ZYXIQ SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026	NE
03-25	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Zynex, Inc. Lawsuit - ZYXIQ	PR
03-24	ZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements	PR

27/12/22	Top 50 Small-caps 2023
21/12/22	Top 50 Small-caps 2023
21/10/21	Los valores del Nasdaq con mayor crecimiento
21/10/21	Les actions du Nasdaq avec la plus forte croissance

Current year	0.02	0.13
1 year	0.02	2.1
3 years	0.02	13.77
5 years	0.02	17.25
10 years	0.02	27.02

Manager	Title	Age	Since
Steven Dyson CEO	Chief Executive Officer	53	17/08/2025
Vikram Bajaj DFI	Director of Finance/CFO	50	17/08/2025
John Bibb LAW	General Counsel	53	17/08/2025

Director	Title	Age	Since
Vikram Bajaj BRD	Director/Board Member	50	25/03/2026
John Bibb BRD	Director/Board Member	53	25/03/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
26/03/26	Barry Michaels	Issuer sale	Director	80,001	0.2633%
26/03/26	Michael Cress	Issuer sale	Director	95,000	0.3126%
26/03/26	Joshua Disbrow	Issuer sale	Director	102,000	0.3357%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ZYNEX, INC.	+5.77%	-.--%	-96.23%	-99.26%	1.69M
THERMO FISHER SCIENTIFIC, INC.	-1.75%	+0.42%	+23.66%	+16.35%	223B
DANAHER CORPORATION	-1.17%	-0.82%	+3.32%	-17.37%	144B
INTUITIVE SURGICAL, INC.	-4.51%	-5.17%	-25.50%	+17.42%	124B
BOSTON SCIENTIFIC CORPORATION	-5.90%	-6.45%	-58.41%	-16.50%	65.19B
EDWARDS LIFESCIENCES CORPORATION	-3.54%	-4.43%	+8.12%	+17.08%	49.99B
SIEMENS HEALTHINEERS AG	+0.98%	-0.76%	-17.96%	-12.69%	50.49B
AGILENT TECHNOLOGIES, INC.	-2.66%	-2.05%	+14.61%	+28.83%	41.4B
WATERS CORPORATION	-1.58%	-0.72%	+30.24%	+52.87%	39.59B
ILLUMINA, INC.	-3.28%	+1.90%	+114.97%	+33.28%	31.87B
Average	-1.19%	-4.04%	-0.32%	+2.00%	76.95B
Weighted average by Cap.	-1.42%	-1.80%	+4.88%	+8.81%

	2023	2024
Net sales	184M 158M 149M 136M 254M 17.47B 255M 1.77B 683M 8.93B 692M 677M 28.42B	192M 165M 156M 142M 265M 18.24B 266M 1.84B 713M 9.32B 722M 707M 29.66B
Net income	9.73M 8.37M 7.87M 7.18M 13.41M 923M 13.48M 93.27M 36.09M 472M 36.54M 35.75M 1.5B	2.99M 2.57M 2.42M 2.21M 4.12M 284M 4.15M 28.69M 11.1M 145M 11.24M 11M 462M
Net Debt	31.59M 27.16M 25.55M 23.32M 43.52M 2.99B 43.74M 303M 117M 1.53B 119M 116M 4.87B	34.19M 29.4M 27.66M 25.24M 47.1M 3.24B 47.35M 328M 127M 1.66B 128M 126M 5.27B